Biogalenic 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   1 Trial   35 News 
  • ||||||||||  Epogen (epoetin alfa) / Amgen
    PK/PD data, Journal:  Pharmacokinetic and pharmacodynamic study of 3 products of epoetin alfa as single subcutaneous dose in healthy volunteers. (Pubmed Central) -  Jan 15, 2023   
    The comparison between Hemax® PFS and Eprex® resulted in similar 90%CI for C , AUC and AUC ratios, all of them within the 80-125% interval, with a power above 95% for each ratio. These findings suggest biosimilar patterns for absorption velocity (with Tmax close to 15 h), absorption extent and elimination (with an elimination half-life close to 25-30 h for each formulation).
  • ||||||||||  Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
    Review, Journal:  Impact of native and external factors on exosome release: understanding reactive exosome secretion and its biogenesis. (Pubmed Central) -  Feb 22, 2022   
    The trading of exosomes between tumor and yonder cells plays a hypercritical role in tumor growth and progression...In this review, we will discuss how the non-native physiological factors influence the release of exosomes and how these reactive exosomes orchestrate a unique patterning of a cargo sorting mechanism. We will also discuss the role of reactively secreted exosomes in mediating tumor metastasis, angiogenesis, and tumor progression.
  • ||||||||||  Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
    Journal:  Diagnosis of hypercritical chronic pulmonary disorders using dense convolutional network through chest radiography. (Pubmed Central) -  Feb 8, 2022   
    The proposed framework shows effective results in classifying lung images into Normal, COVID-pneumonia, pneumonia, and other chronic pulmonary disorders (OCPD). This framework can be effectively utilized in this current pandemic scenario to help the radiologist in substantiating their diagnosis and in starting well in time treatment of these deadly lung diseases.
  • ||||||||||  Epoyet (epoetin alfa biosimilar) / Procaps, Biosidus, Biogalenic, Delta Farma, Pentafarma
    Clinical, Journal:  Distinguishing online academic bullying: identifying new forms of harassment in a dissenting Emeritus Professor's case. (Pubmed Central) -  Mar 16, 2021   
    Such scholars may face an asymmetrical challenge in confronting cyber harassment from hypercritical academics and cybermobs on poorly moderated platforms. Universities should therefor consider appropriate countermeasures to protect both the public and their employees against victimisation by academic cyberbullies.
  • ||||||||||  Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
    Enrollment closed, Trial completion date, Trial primary completion date:  Study of HEMAX PFS Versus EPREX/ ERYPO (clinicaltrials.gov) -  Jan 27, 2021   
    P3,  N=120, Active, not recruiting, 
    Universities should therefor consider appropriate countermeasures to protect both the public and their employees against victimisation by academic cyberbullies. Recruiting --> Active, not recruiting | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Sep 2020 --> Jul 2021
  • ||||||||||  Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
    New P3 trial:  Study of HEMAX PFS Versus EPREX/ ERYPO (clinicaltrials.gov) -  Jul 28, 2019   
    P3,  N=120, Recruiting, 
  • ||||||||||  Epoyet (epoetin alfa biosimilar) / Procaps, Biogalenic, Delta Farma, Biosidus, Pentafarma
    Trial completion, Trial primary completion date:  Epoetin Alfa (Hemax (clinicaltrials.gov) -  Apr 7, 2016   
    P4,  N=30, Completed, 
    The method is suitable for activating rapid-response teams in case of hypercritical values. Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Nov 2014